REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical Company Ltd
RNS Number : 2620ASociete Generale SA10 September 2018FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser:
Société Générale S.A.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical CO LTD
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
07/09/2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES: Shire PLC
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
2,696,412
0.34
6,280,881
0.80
(2) Cash-settled derivatives:
5,259,342
0.67
2,026
0.00
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
121,500
0.02
0
0.00
TOTAL:
8,077,254
1.03
6,282,907
0.80
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
JPY
Ordinary
Purchase
5,600
4425
Ordinary
Purchase
100
4379
Ordinary
Purchase
300
4406
Ordinary
Purchase
900
4379
Ordinary
Purchase
200
4378
Ordinary
Purchase
600
4371
Ordinary
Purchase
500
4371
Ordinary
Purchase
500
4355
Ordinary
Purchase
400
4381
Ordinary
Purchase
500
4380
Ordinary
Purchase
500
4380
Ordinary
Purchase
800
4378
Ordinary
Purchase
300
4373
Ordinary
Purchase
100
4407
Ordinary
Purchase
100
4407
Ordinary
Purchase
200
4405
Ordinary
Purchase
100
4405
Ordinary
Purchase
600
4371
Ordinary
Purchase
1,200
4354
Ordinary
Purchase
800
4376
Ordinary
Purchase
2,300
4373
Ordinary
Purchase
1,300
4423
Ordinary
Purchase
300
4423
Ordinary
Purchase
3,000
4382
Ordinary
Purchase
100
4349
Ordinary
Purchase
2,300
4354
Ordinary
Purchase
100
4371
Ordinary
Purchase
500
4363
Ordinary
Purchase
1,400
4347
Ordinary
Purchase
700
4367
Ordinary
Purchase
1,100
4372
Ordinary
Purchase
2,200
4375
Ordinary
Purchase
200
4412
Ordinary
Purchase
100
4424
Ordinary
Purchase
100
4396
Ordinary
Purchase
600
4391
Ordinary
Purchase
100
4390
Ordinary
Purchase
400
4347
Ordinary
Purchase
500
4357
Ordinary
Purchase
1,100
4360
Ordinary
Purchase
1,100
4359
Ordinary
Purchase
1,000
4377
Ordinary
Purchase
1,000
4378
Ordinary
Purchase
1,000
4383
Ordinary
Purchase
700
4384
Ordinary
Purchase
1,000
4400
Ordinary
Purchase
1,000
4400
Ordinary
Purchase
700
4368
Ordinary
Purchase
600
4345
Ordinary
Purchase
1,000
4386
Ordinary
Purchase
700
4386
Ordinary
Purchase
1,000
4394
Ordinary
Purchase
300
4394
Ordinary
Purchase
300
4400
Ordinary
Purchase
700
4346
Ordinary
Purchase
100
4400
Ordinary
Purchase
1,000
4401
Ordinary
Purchase
100
4397
Ordinary
Purchase
1,300
4349
Ordinary
Purchase
500
4393
Ordinary
Purchase
1,000
4392
Ordinary
Purchase
1,100
4368
Ordinary
Purchase
1,100
4367
Ordinary
Purchase
200
4372
Ordinary
Purchase
400
4348.5
Ordinary
Purchase
500
4396.5
Ordinary
Purchase
400
4395
Ordinary
Purchase
600
4416
Ordinary
Purchase
100
4367
Ordinary
Purchase
300
4381
Ordinary
Purchase
1,200
4379.5
Ordinary
Purchase
400
4352
Ordinary
Purchase
700
4413
Ordinary
Purchase
400
4407
Ordinary
Purchase
100
4368
Ordinary
Purchase
200
4374
Ordinary
Purchase
2,300
4374
Ordinary
Purchase
14,200
4374
Ordinary
Purchase
100
4390
Ordinary
Purchase
300
4420
Ordinary
Purchase
100
4412
Ordinary
Purchase
100
4410
Ordinary
Purchase
200
4405
Ordinary
Purchase
100
4407
Ordinary
Purchase
174
4488
Ordinary
Sale
14,700
4374
Ordinary
Sale
300
4375
Ordinary
Sale
300
4410
Ordinary
Sale
200
4410
Ordinary
Sale
500
4375
Ordinary
Sale
100
4345
Ordinary
Sale
1,300
4395
Ordinary
Sale
100
4400
Ordinary
Sale
700
4398
Ordinary
Sale
200
4384
Ordinary
Sale
400
4369
Ordinary
Sale
200
4397
Ordinary
Sale
1,300
4416
Ordinary
Sale
100
4376
Ordinary
Sale
900
4363
Ordinary
Sale
700
4366
Ordinary
Sale
500
4369
Ordinary
Sale
200
4366
Ordinary
Sale
500
4369
Ordinary
Sale
800
4369
Ordinary
Sale
100
4366
Ordinary
Sale
1,800
4366
Ordinary
Sale
700
4361
Ordinary
Sale
1,700
4377
Ordinary
Sale
200
4410
Ordinary
Sale
100
4368
Ordinary
Sale
1,100
4388
Ordinary
Sale
100
4361
Ordinary
Sale
1,500
4380
Ordinary
Sale
200
4345
Ordinary
Sale
1,200
4354
Ordinary
Sale
1,400
4398
Ordinary
Sale
500
4368
Ordinary
Sale
600
4384
Ordinary
Sale
800
4385
Ordinary
Sale
2,300
4373
Ordinary
Sale
100
4417
Ordinary
Sale
1,000
4418
Ordinary
Sale
1,700
4384
Ordinary
Sale
2,300
4352
Ordinary
Sale
100
4386
Ordinary
Sale
1,300
4395
Ordinary
Sale
300
4384
Ordinary
Sale
300
4368
Ordinary
Sale
200
4396
Ordinary
Sale
800
4411
Ordinary
Sale
200
4344
Ordinary
Sale
100
4419
Ordinary
Sale
1,100
4419
Ordinary
Sale
400
4420
Ordinary
Sale
1,000
4398
Ordinary
Sale
100
4398
Ordinary
Sale
1,300
4395
Ordinary
Sale
700
4405
Ordinary
Sale
1,300
4378
Ordinary
Sale
100
4417
Ordinary
Sale
600
4409
Ordinary
Sale
1,700
4380
Ordinary
Sale
800
4415
Ordinary
Sale
200
4403
Ordinary
Sale
200
4408
Ordinary
Sale
100
4399
Ordinary
Sale
200
4399
Ordinary
Sale
200
4403
Ordinary
Sale
300
4397
Ordinary
Sale
100
4383
Ordinary
Sale
300
4384
Ordinary
Sale
800
4384
Ordinary
Sale
100
4384
Ordinary
Sale
1,000
4384
Ordinary
Sale
200
4403
Ordinary
Sale
100
4398
Ordinary
Sale
200
4410
Ordinary
Sale
200
4408
Ordinary
Sale
100
4408
Ordinary
Sale
1,300
4383
Ordinary
Sale
400
4405
Ordinary
Sale
1,000
4372
Ordinary
Sale
1,000
4426
Ordinary
Sale
1,100
4350
Ordinary
Sale
900
4378
Ordinary
Sale
1,000
4374
Ordinary
Sale
1,100
4354
Ordinary
Sale
900
4374
Ordinary
Sale
1,100
4351
Ordinary
Sale
1,100
4361
Ordinary
Sale
400
4348
Ordinary
Sale
1,000
4382
Ordinary
Sale
900
4375
Ordinary
Sale
400
4355
Ordinary
Sale
1,000
4383
Ordinary
Sale
500
4414
Ordinary
Sale
300
4385
Ordinary
Sale
200
4380.5
Ordinary
Sale
200
4364.5
Ordinary
Sale
200
4368.5
Ordinary
Sale
100
4380
Ordinary
Sale
1,900
4374
Ordinary
Sale
800
4374
Ordinary
Sale
100
4379
Ordinary
Sale
8,000
4374
Ordinary
Sale
100
4354
Ordinary
Sale
11,000
4374
Ordinary
Sale
189
4558
Total Purchases
74,074
Total Sales
98,289
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit JPY
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit JPY
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable) JPY
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
YES
Date of disclosure:
10/09/2018
Contact name:
Olivier Vero
Telephone number:
+44 20 7676 6969
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
1. KEY INFORMATION
Full name of person making disclosure:
SOCIETE GENERALE SA
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:
Takeda Pharmaceutical CO LTD
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security
Product description e.g. call option
Written or purchased
Number of securities to which option or derivative relates
Exercise price per unit
Type
Expiry date
JPY
e.g. American, European etc.
Ordinary
OTC put-option
Sale
15,700
4707
European options
14/12/2018
Ordinary
OTC put-option
Sale
30,000
5075.10
European options
14/12/2018
Ordinary
OTC put-option
Sale
29,600
5073.65
European options
14/12/2018
Ordinary
OTC put-option
Sale
15,500
4491.40
European options
14/12/2018
Ordinary
OTC put-option
Sale
30,700
4533.90
European options
14/12/2018
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRETSFWSASFASELU
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement